Search

The Sfeir Lab investigates pathways that ensure genome fidelity and plasticity.

… Chromosomes are the fundamental structural units of our genome. The Sfeir lab seeks to understand basic chromosome biology and how their mismanagement manifests in disease. Our research is focused on three major areas: telomere maintenance, nuclear DNA repair, and mitochondrial DNA replication and repair

Physician-scientist Richard Wong studies the mechanisms of cancer cell chemotaxis in perineural invasion.

… Perineural invasion (PNI) is an ominous form of cancer progression in which cancer cells invade and track along nerves. PNI occurs most frequently in cancers that affect highly innervated organs, including pancreatic, head and neck, and prostate cancers. It is associated with increased recurrence and

Physician-scientist Aimee Crago studies mechanisms by which common genomic events drive initiation and progression of soft tissue tumors.

… The rarity of soft tissue sarcomas has historically made the definition of genomic drivers of their initiation and progression difficult.  Through copy number, whole exome and transcriptome analyses, however, common events associated with these lesions have recently been defined.  The focus of our laboratory

The Romesser lab studies colorectal and anal cancer with a focus on using radiotherapy to treat disease.

… Research of the Paul Romesser Laboratory focuses on three main concepts. First is the characterization of the processes of senescence. This includes senescence-associated secretory phenotype (SASP) induction and tumor microenvironment (TME) remodeling in response to radiation. Similarly, we seek to investigate

Physician-scientist Andrew Intlekofer investigates why cancer cells depend on specific pathways of nutrient metabolism.

… Andrew Intlekofer is an Assistant Member in the Human Oncology and Pathogenesis Program and an Attending Physician on the Lymphoma Service in the Department of Medicine. Dr. Intlekofer’s research investigates how deregulated metabolic pathways contribute to cancer development and how metabolic enzymes

Interventional radiologist Constantinos Sofocleous leads research in the optimization of image-guided therapies for colorectal cancer metastases.

… The Constantinos Sofocleous Lab focuses in the exploration, assessment, and validation of tissue and image biomarkers after local and locoregional therapies for metastatic colorectal cancer. The research staff includes experts in radiation physics, 3D software applications in medicine, histopathology

The Zallen laboratory focuses on the generation of tissue structure through the collective action of cell populations.

… Our lab focuses on the generation of tissue structure through the collective action of cell populations. Jennifer A. Zallen, PhD Member, Developmental Biology Program, SKI; Investigator, Howard Hughes Medical Institute Professor PhD, University of California, San Francisco Email [email protected] Laboratory

Cancer biologist Michael Kharas studies RNA regulators of self-renewal in both normal and leukemic hematopoiesis.

… The Kharas lab is working to identify critical pathways in both normal and leukemic hematopoietic cells. Michael G. Kharas, PhD Professor PhD, University of California Irvine Achievements Leukemia and Lymphoma Society Career Development Award (2017) Alex Lemonade Stand Foundation ‘A’ Award (2016) American

Physician-scientist Nai-Kong Cheung focuses on engineering antibodies and immune cells to treat both solid tumors and liquid tumors in children.

… My lab focuses on engineering antibodies and immune cells to treat both solid tumors and liquid tumors in children. Nai-Kong V. Cheung, MD, PhD Enid A. Haupt Chair in Pediatric Oncology, Pediatrics Professor MD, PhD (Immunology), Harvard Medical School Email [email protected] Laboratory phone 646-888

Physician-scientist Christopher A. Klebanoff studies T cell immunobiology with an emphasis on adoptive T cell immunotherapy for the treatment of solid malignancies.

… A form of cancer immunotherapy termed adoptive T cell transfer (ACT), in which a patient’s own T cells are engineered to recognize and attack cancer cells, can induce durable complete remissions in patients with advanced hematologic malignancies. By contrast, a similar approach has thus far failed to